Document is current

Article History

Received: 15 December 2022

Accepted: 30 March 2023

First Online: 22 April 2023

Competing interests

: K.V. currently receives research funding from Cepheid and collaborates with Optra Health. R.B.S. is a co-founder of and holds equity in Delfi Diagnostics. He also serves as a consultant. V.E.V. is a founder of Delfi Diagnostics, serves on the Board of Directors and as an officer for this organization, and owns Delfi Diagnostics stock, which is subject to certain restrictions under university policy. Additionally, Johns Hopkins University owns equity in Delfi Diagnostics. V.E.V. divested his equity in Personal Genome Diagnostics (PGDx) to LabCorp in February 2022. V.E.V. is an inventor on patent applications submitted by Johns Hopkins University related to cancer genomic analyses and cell-free DNA for cancer detection that have been licensed to one or more entities, including Delfi Diagnostics, LabCorp, Qiagen, Sysmex, Agios, Genzyme, Esoterix, Ventana and ManaT Bio. Under the terms of these license agreements, the University and inventors are entitled to fees and royalty distributions. V.E.V. is an advisor to Viron Therapeutics and Epitope. These arrangements have been reviewed and approved by the Johns Hopkins University in accordance with its conflict-of-interest policies. These arrangements have been reviewed and approved by Johns Hopkins University in accordance with its conflict-of-interest policies. The remaining authors declare no competing interests.